Xcorporeal Stock

Xcorporeal Equity

The The Equity of Xcorporeal (XCRP) as of Aug 4, 2026 is -2.04 M USD.

Equity

-2.04 MUSD

Last updated:

In 2026, Xcorporeal's equity was -2.04 M USD, a % increase from the - USD equity in the previous year.

Access this data via the Eulerpool API

Xcorporeal Stock analysis

What does Xcorporeal do? Xcorporeal Inc is an American medical technology company specialized in the development and marketing of innovative medical devices. The company was founded in 2002 and is headquartered in Los Angeles, California. The company operates in the field of extracorporeal therapy, where blood is cleansed outside the body. The goal is to rid the body of toxins and excess fluids when the kidneys or liver are not functioning properly. Xcorporeal Inc's business model is based on the development and marketing of extracorporeal therapy devices. The company aims to lead in the field of renal replacement therapy, blood purification, and soluble sepsis treatment. In this context, Xcorporeal Inc is a pioneer in the field of portable hemodialysis devices, which allow patients to receive continuous kidney function treatment. The devices are designed to be easy to use and provide patients with mobility and quality of life. Xcorporeal Inc offers a variety of products tailored to the needs of patients and medical personnel. The portable hemodialysis device FloWatch is one of Xcorporeal Inc's most well-known products. It allows patients to perform treatment at home, providing them with more flexibility and self-determination. Additionally, Xcorporeal Inc has also developed a solution for the treatment of sepsis. Soluble Sepsis Therapy (SST) is a groundbreaking procedure in which blood is pumped through a special filter technology to remove dangerous toxins and inflammatory substances from the blood. Xcorporeal Inc currently operates two divisions focused on other applications of extracorporeal therapy. The first division focuses on the development of devices for blood purification and fighting infections. The second division is involved in the development of medical instruments for use in research and development. Overall, Xcorporeal Inc has the potential to change the face of extracorporeal therapy. With its innovative products and pioneering spirit in the field of portable hemodialysis devices, the company has shown that it is capable of transforming the market and revolutionizing the way extracorporeal therapy is practiced. Xcorporeal is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Xcorporeal's Equity

Xcorporeal's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Xcorporeal's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Xcorporeal's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Xcorporeal's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Xcorporeal’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Xcorporeal stock

The Equity of Xcorporeal is -2.04 M USD in 2026.

On Eulerpool you can find the complete historical development of The Equity Xcorporeal since 2006 – with annual values, charts, and detailed analysis.

The Equity's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Xcorporeal historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Xcorporeal

All Key Metrics — Xcorporeal